Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
University of Pennsylvania Cancer Center
Last Modified: November 1, 2001
For Immediate Release, October 23, 1997
(Philadelphia, PA)--Researchers at The University of Pennsylvania Cancer Center are leading an international, multi-site study on the performance characteristics of Magnetic Resonance Imaging (MRI) in detecting and diagnosing lesions in approximately 3,000 patients with suspicious mammograms. The study will also examine the extent of cancer growth within affected breasts and will investigate the feasibility of using MRI to assess patients who carry a genetic risk of inheriting breast cancer.
Approximately $5 million has been provided by the National Cancer Institute in support of this study, which marks the largest grant given to date for breast MRI research
Physicians at Penn have long been at the forefront of MR and other imaging research. "This study should prove that MRI is by far the best diagnostic tool for detecting breast cancer," says principal investigator Mitchell Schnall, MD, PhD, who serves as Chief of the MRI Section at the Hospital of the University of Pennsylvania. "Breast MRI has the capability of finding small cancerous lesions often missed by regular mammograms and routine self examinations, thereby increasing a patient's chance for survival."
Breast cancer is the most frequently diagnosed malignancy in the United States and ranks as the second leading cause of cancer deaths in women. Most missed cancers, however, occur in patients with dense breast tissue. Compared to mammography, breast MRI provides higher soft tissue contrast, which allows for more accurate lesion detection and better image enhancement.
MRI is not routinely used in clinical practice because of its expense, but its use for catching cancer at its earliest stage may ultimately prove cost-effective. Surgical biopsies could be avoided if breast MRI can show that a lesion is definitely benign. Separate studies have already demonstrated the potential for breast MRI to distinguish benign from malignant breast lesions and to detect clinically mysterious cancer.
Another added advantage for using breast MRI is its potential for determining how far the cancer has spread within the breast. "Knowing the extent of cancer within a breast would impact a patient's decision on the type of breast conservation therapy chosen--and that would mean the difference between choosing a mastectomy and a lumpectomy," Schnall explains. "We hope to confirm the results of smaller populated studies, which have proven that breast MRI is extremely effective in image enhancement and very specific in small lesion detection," he concluded.
The 14 clinical sites involved in the four-year study include experts in breast imaging, clinical MRI and MR physics and technical industry experts in the use of MRI equipment and contrasting agents.
Dr. Giantonio discusses the importance of oncology clinical trials and clarifies some myths about studies. Read more.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Cladribine (2-CDA, Leustatin®)
Cyclophosphamide (Cytoxan®, Neosar®, Endoxan®)
Cyclosporine (Neoral®, Sandimmune®, Restasis®, Gengraf®)
Cytarabine (Cytosar-U®, Ara-C)
Irinotecan (Camptosar®, CPT-11)
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Calcium Leucovorin, Citrovorum Factor, Folinic Acid
Leucovorin (Calcium Leucovorin, Citrovorum Factor, Folinic Acid)
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Men
Leuprolide Acetate (Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®) - For Women
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Lupron®, Lupron Depot®, Eligard®, Prostap®, Viadur®
Busulfan (Myleran®, Busulfex®)
Intravesicular Mitomycin (Mutamycin®, Mitomycin-C, given into the bladder)
Mechlorethamine (Mustargen®, Nitrogen Mustard)
mechlorethamine, mustine, Mustargen®
Megestrol (Megace®, Megace-ES®)
Mercaptopurine (Purinethol®, 6-MP)
Methotrexate (Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX)
Mexate®, Folex®, Rheumatrex®, Amethopterin, MTX
Mitomycin (Mutamycin®, Mitomycin-C)
Morphine Sulfate (Given by IV)
Morphine Sulfate (MS Contin®, Avinza®, Kadian®, Oramorph SR®)
MS Contin®, Avinza®, Kadian®, Oramorph SR®
Mutamycin®, Mitomycin-C, given into the bladder
Nitrogen mustard (mechlorethamine, mustine, Mustargen®)
Bendamustine Hydrochloride (Treanda®)
Bexarotene (Targretin®), Oral Formulation
Bexarotene Gel (Targretin® Gel Formulation)
Etoposide (Toposar®, VePesid®, Etopophos®,VP-16)
Thioguanine (6-TG, Thioguanine Tabloid®)
Toposar®, VePesid®, Etopophos®,VP-16
Trelstar LA® and Trelstar Depot®
Tretinoin (Vesanoid®, All-Trans-Retinoic Acid, ATRA)
Triptorelin (Trelstar LA® and Trelstar Depot®)

